| HOME >> BIOLOGY >> TECHNOLOGY |
American Academy of Allergy, Asthma & Immunology (AAAAI) in
Philadelphia, PA.
-- New pre-clinical findings on the treatment of prostate cancer models
at the American Association for Cancer Research conference. The
studies explored the physiologic responses to enzymatic removal of
hyaluronic acid (HA)-based matrices surrounding tumor cells in the
tumor microenvironment of prostate tumors following systemic
administration of its pegylated rHuPH20 (PEG PH20) pre-clinical
candidate. The objectives of these studies were to determine whether
HA-dependent pericellular matrices produced in vitro and in vivo by a
hormone refractory prostate cancer cell line could be enzymatically
depleted in prostate carcinoma xenografts following intravenous (IV)
administration of the PEG PH20 enzyme. In mice, IV PEG PH20 collapsed
the protective HA-based pericellular matrices of prostate cancer cells
and selectively increased tumor vascular volume 3.5-fold.
-- Findings on the local tolerability and pharmacokinetics of
bisphosphonates combined with PH20 at the American Association for
Cancer Research conference. The objectives of the presented studies
were to investigate in animal models whether increasing the dispersion
and absorption of bisphosphonates in the skin and subcutaneous tissues
with PH20 could modify injection site reaction profiles from two
intravenous bisphosphonate formulations, zoledronic acid and
ibandronate. The pharmacokinetics of bisphosphonates in blood were
also examined and compared to intravenous infusion. The maximal
concentration of bisphosphonates that could be administered without
producing injection site reactions was increased 3-to-5 fold when
co-administered
'/>"/>
| SOURCE Halozyme Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |